Biosplice Therapeutics Stock
Tissue-Level Regeneration
Sign up today and learn more about Biosplice Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Biosplice Therapeutics Stock
Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.
Investors
Starling group
Vickers Venture Partners
Polar Light Ventures
Esas Ventures
Sands Capital Management
Funding History
| February 2021 | $60.0M |
|---|---|
| March 2021 | $60.0M |
Management
Chief Executive Officer
Samikoglu Cevdet
Chief Financial Officer
Horsley Erich
Press
globenewswire - Apr, 8 2024
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp ...finance - Mar, 3 2024
Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial ...globenewswire - Dec, 20 2023
Knee Osteoarthritis Market to Witness Upsurge in Growth ...appliedclinicaltrialsonline - Dec, 20 2023
Osteoarthritis: Is a Cure on the Launch Pad?medgadget - Dec, 20 2023
Degenerative Disc Disease Clinical Trial Pipeline Insights | 15 ...EquityZen Recognized As:
